Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant gemcitabine + capecitabine vs capecitabine alone in resected biliary tract cancer
KCT0005056Phase 3Not yet recruiting
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Aug 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemcitabine, capecitabine in biliary cancer, sponsored by Ildong Pharmaceutical Co Ltd. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
gemcitabinecapecitabine
03
Conditions
biliary cancer
Beyond the preview
Go deeper on KCT0005056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005056.